Cargando…

HER2 overexpression in ductal carcinoma in situ is associated with ipsilateral breast cancer recurrence after conservative surgery

BACKGROUND: A few patients with ductal carcinoma in situ (DCIS) after breast conservative surgery would develop ipsilateral breast cancer recurrence (IBTR), either invasive or non-invasive. Study of accurate predictive biomarkers for IBTR risk are warranted. We analyzed the association of human epid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Di-He, Ge, Jin-Yu, Chen, Yi-Yu, Ding, Ke-Feng, Yu, Ke-Da
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797760/ https://www.ncbi.nlm.nih.gov/pubmed/35117746 http://dx.doi.org/10.21037/tcr-20-1481

Ejemplares similares

Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer
por: Choi, Young Jin, et al.
Publicado: (2016)

Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
por: Qu, Fei-Lin, et al.
Publicado: (2022)

Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery
por: Kim, Jung Yeon, et al.
Publicado: (2016)

Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ()
por: Darvishian, Farbod, et al.
Publicado: (2022)

Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting
por: Habel, Laurel A, et al.
Publicado: (2009)

Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
por: Gosset, Marie, et al.
Publicado: (2016)

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
por: Rakovitch, E, et al.
Publicado: (2012)

Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast
por: van Seijen, Maartje, et al.
Publicado: (2021)

Molecular subtypes predict second breast events of ductal carcinoma in situ after breast‐conserving surgery
por: Yang, Yilan, et al.
Publicado: (2022)

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
por: Almekinders, Mathilde M. M., et al.
Publicado: (2021)

Evaluation of automated breast volume scanner for breast conservation surgery in ductal carcinoma in situ
por: Huang, Anqian, et al.
Publicado: (2016)

Radiotherapy after Conservative Surgery in Ductal Carcinoma In Situ of the Breast: A Review
por: Amichetti, Maurizio, et al.
Publicado: (2012)

Impact of consensus guidelines for breast‐conserving surgery in patients with ductal carcinoma in situ
por: Tremelling, Abigail, et al.
Publicado: (2021)

Survival outcomes after breast-conserving surgery plus radiotherapy compared with mastectomy in breast ductal carcinoma in situ with microinvasion
por: Xia, Lin-Yu, et al.
Publicado: (2022)

Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy
por: Pawloski, Kate R., et al.
Publicado: (2021)

Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ
por: Tamura, Nobuko, et al.
Publicado: (2015)

Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery?
por: Kim, Taeryung, et al.
Publicado: (2014)

Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery
por: Qu, Fei-Lin, et al.
Publicado: (2021)

Repeat Breast-Conserving Surgery Versus Salvage Mastectomy for Ipsilateral Breast Tumour Recurrence After Breast-Conserving Surgery in Breast Cancer Patients: A Meta-Analysis
por: Mo, Caiqin, et al.
Publicado: (2021)

Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis
por: Yu, Qiuyan, et al.
Publicado: (2015)

The Feasibility of Omitting Postoperative Radiotherapy in Japanese Patients With Ductal Carcinoma In Situ of Breast Treated With Breast-Conserving Surgery
por: Nakashima, Akihiro, et al.
Publicado: (2023)

Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience
por: Cutuli, B, et al.
Publicado: (2009)

The Efficacy of Intraoperative Frozen Section Analysis During Breast-Conserving Surgery for Patients with Ductal Carcinoma In Situ
por: Kim, Mi Jin, et al.
Publicado: (2016)

Magnetic resonance imaging based 3-dimensional printed breast surgical guide for breast-conserving surgery in ductal carcinoma in situ: a clinical trial
por: Wu, Zhen-Yu, et al.
Publicado: (2020)

Independent Prognostic Factors for Overall Survival after Salvage Operation for Ipsilateral Breast Tumor Recurrence Following Breast-Conserving Surgery
por: Lee, Jun Hee, et al.
Publicado: (2015)

Is conservative management of ductal carcinoma in situ risky?
por: Zheng, Lan, et al.
Publicado: (2022)

A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay
por: Lei, Rachel Y., et al.
Publicado: (2020)

Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk
por: Almekinders, Mathilde M., et al.
Publicado: (2022)

Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells
por: Agahozo, Marie Colombe, et al.
Publicado: (2021)

Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials
por: Viani, Gustavo A, et al.
Publicado: (2007)

Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
por: Millis, R R, et al.
Publicado: (2004)

Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2
por: Solek, Julia, et al.
Publicado: (2022)

Ductal Carcinoma In Situ of the Breast
por: Lee, Richard J., et al.
Publicado: (2012)

Breast Ductal Carcinoma In Situ
por: Sacchini, Virgilio, et al.
Publicado: (2012)

Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression
por: Smith, Yvonne E., et al.
Publicado: (2022)

Systematic review of the impact of breast‐conserving surgery on cancer outcomes of multiple ipsilateral breast cancers
por: Winters, Z. E., et al.
Publicado: (2018)

Breast-conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up
por: Carrara, Guilherme Freire Angotti, et al.
Publicado: (2017)

Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Breast-Conserving Surgery
por: Cheun, Jong-Ho, et al.
Publicado: (2021)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Effect of radiotherapy after breast-conserving surgery in older patients with early breast cancer and breast ductal carcinoma in situ: a meta-analysis
por: Huang, Xuan-zhang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8935t9vmv6k1ofh6be416lmijg